Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer

American Journal of Obstetrics and Gynecology

Volumn 197, Issue 2, 2007, Pages 139.e1-139.e7

  Doherty, Jennifer A ^a   Cushing Haugen, Kara L ^a   Saltzman, Babette S ^a,b   Voigt, Lynda F ^a,b   Hill, Deirdre A ^d   Beresford, Shirley A ^a,b   Chen, Chu ^a,b,c   Weiss, Noel S ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

endometrial cancer; estrogen; hormone therapy; menopause; progestin

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; ARTICLE; CANCER RISK; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HORMONAL THERAPY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; TIME SERIES ANALYSIS;

EID: 34547572363     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.01.019     Document Type: Article

References (28)

1. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280 (1998) 605-613
2. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
3. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291 (2004) 47-53
4. Coope J., Thomson J.M., and Poller L. Effects of "natural oestrogen" replacement therapy on menopausal symptoms and blood clotting. BMJ 4 (1975) 139-143
5. Cauley J.A., Robbins J., Chen Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290 (2003) 1729-1738
6. Cook L.S., and Weiss N.S. Endometrial cancer. In: Goldman M.B., and Hatch M.C. (Eds). Women & health (2000), Academic Press, London 916-931
7. Beresford S.A., Weiss N.S., Voigt L.F., and McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349 (1997) 458-461
8. Weiderpass E., Adami H.O., Baron J.A., et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91 (1999) 1131-1137
9. Beral V., Bull D., Reeves G., and Million Women Study collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (2005) 1543-1551
10. Pike M.C., Peters R.K., Cozen W., et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89 (1997) 1110-1116
11. Strom B.L., Schinnar R., Weber A.L., et al. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am J Epidemiol 164 (2006) 775-786
12. Newcomb P.A., and Trentham-Dietz A. Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control 14 (2003) 195-201
13. Jain M.G., Rohan T.E., and Howe G.R. Hormone replacement therapy and endometrial cancer in Ontario, Canada. J Clin Epidemiol 53 (2000) 385-391
14. Lacey J.V., Brinton L.A., Lubin J.H., and Sherman M.E. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 14 (2005) 1724-1731
15. Hill D.A., Weiss N.S., Beresford S.A., et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 183 (2000) 1456-1461
16. Marchbanks P.A., McDonald J.A., Wilson H.G., et al. The NICHD women's contraceptive and reproductive experiences study: methods and operational results. Ann Epidemiol 12 (2002) 213-221
17. Hankey B.F., Ries L.A., and Edwards B.K. The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 8 (1999) 1117-1121
18. Waksberg J. Sampling methods for random digit dialing. J Am Stat Assoc 73 (1978) 40-46
19. Voigt L.F., Weiss N.S., Chu J., Daling J.R., McKnight B., and van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 338 (1991) 274-277
20. Jain M.G., Rohan T.E., and Howe G.R. Agreement of self-reported use of menopausal hormone replacement therapy with physician reports. Epidemiology 10 (1999) 260-263
21. Strom B.L., and Schinnar R. An interview strategy was critical for obtaining valid information on the use of hormone replacement therapy. J Clin Epidemiol 57 (2004) 1210-1213
22. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial: the Writing Group for the PEPI trial. JAMA 275 (1996) 370-375
23. Anderson G.L., Judd H.L., Kaunitz A.M., et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 290 (2003) 1739-1748
24. Koepsell T.D., and Weiss N.S. Epidemiologic methods: studying the occurrence of illness (2003), Oxford University Press, New York 328
25. Reed S.D., Voigt L.F., Beresford S.A., Hill D.A., Doherty J.A., and Weiss N.S. Dose of progestin in postmenopausal-combined hormone therapy and risk of endometrial cancer. Am J Obstet Gynecol 191 (2004) 1146-1151
26. Persson I., Weiderpass E., Bergkvist L., Bergstrom R., and Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 10 (1999) 253-260
27. Jick S.S., Walker A.M., and Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology 4 (1993) 20-24
28. Brinton L.A., and Hoover R.N. Estrogen replacement therapy and endometrial cancer risk: unresolved issues: the Endometrial Cancer Collaborative group. Obstet Gynecol 81 (1993) 265-271